Table 2.

Overview of patient and disease characteristics

	MDR TB (%) (n = 8)	DR-TB (%) except MDR-TB (n =)	Total (% of total) (n = 16)
Start of treatment (year)
2009–2014	4 (50)	2 (25)	6 (37.5)
2015–2020	4 (50)	6 (75)	10 (62.5)
Duration of treatment (months)
9–12	3 (37.5)	6 (75)	9 (56.3)
13–18	1 (12.5)	2 (25)	3 (18.7)
> 19	4 (50)		4 (25)
Site of infection
Lung	6 (75)	2 (25)	8 (50)
Abdomen	1 (12.5)	2 (25)	3 (18.75)
Skeleton/ skin		2 (25)	2 (12.5)
Lymph node	1 (12.5)	2 (25)	3 (18.75)
Participant reported healthcare delay
Participants	3 (37.5)	5 (62.5)	8 (50)